Vraylar (Cariprazine; Gedeon Richter/Allergan/Mitsubishi Tanabe) Drug Outlook to 2026: Bipolar Disorder, Schizophrenia and Depression - ResearchAndMarkets.com

The "Drug Overview: Vraylar" report has been added to ResearchAndMarkets.com's offering.

Vraylar (cariprazine; Gedeon Richter/Allergan/Mitsubishi Tanabe) is a novel atypical antipsychotic with partial agonistic activity at D2 and D3 receptors, and selectivity for the D3 receptor. Vraylar is also a partial agonist at 5-HT1A receptors and an antagonist at 5-HT2A receptors. Most atypical antipsychotics have full antagonistic activity at D2 and 5-HT2A receptors, giving cariprazine a unique pharmacology among drugs in the class.

Vraylar was initially developed as a drug for schizophrenia and bipolar disorder, and is now being investigated for the adjunctive treatment of major depressive disorder (MDD) as a line extension. Allergan has so far completed a single Phase III trial in MDD, which yielded negative data. Vraylar was first approved by the US Food and Drug Administration in September 2015.

Key Topics Covered

1. Drug Overview
2. Product Profiles
3. Vraylar: Bipolar Disorder
4. Vraylar: Schizophrenia
5. Vraylar: Depression

List of Figures

Figure 1: Vraylar for bipolar disorder - SWOT analysis

Figure 2: Drug assessment summary for Vraylar in bipolar disorder

Figure 3: Drug assessment summary for Vraylar in bipolar disorder

Figure 4: Vraylar for schizophrenia - SWOT analysis

Figure 5: Drug assessment summary of Vraylar for schizophrenia

Figure 6: Drug assessment summary of Vraylar for schizophrenia

Figure 7: Vraylar sales for schizophrenia across the US and five major EU markets, by country, 2017-26

Figure 8: Vraylar for depression - SWOT analysis

Figure 9: Drug assessment summary for Vraylar in depression

Figure 10: Drug assessment summary for Vraylar in depression

List of Tables

Table 1: Vraylar bipolar disorder indication approvals

Table 2: Vraylar drug profile

Table 3: Overview of key pivotal trial data for Vraylar in bipolar disorder

Table 4: Key side effects (=5%) reported in clinical trials of Vraylar monotherapy for bipolar mania

Table 5: Vraylar Phase III trials in bipolar depression

Table 6: Vraylar drug profile

Table 7: Vraylar pivotal trial data in schizophrenia

Table 8: Vraylar other late-phase trial data in schizophrenia

Table 9: Vraylar sales for schizophrenia across the US and five major EU markets, by country M, 2017-26

Table 10: Vraylar drug profile

Table 11: Vraylar Phase II and III data in depression

For more information about this report visit https://www.researchandmarkets.com/research/s4q4h9/vraylar?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20180511005740/en/